|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||535.64 - 535.64|
|52 Week Range||337.90 - 653.00|
|Beta (5Y Monthly)||0.10|
|PE Ratio (TTM)||104.11|
|Forward Dividend & Yield||0.80 (0.17%)|
|Ex-Dividend Date||Mar. 29, 2021|
|1y Target Est||N/A|
SARTORIUS (SARTF) possesses solid growth attributes, which could help it handily outperform the market.
SARTORIUS (SARTF) delivered earnings and revenue surprises of 7.59% and 5.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has entered into a partnership with McMaster University to improve manufacturing processes of antibody and virus-based treatments for diseases such as COVID-19, cancers, and genetic disorders.